Amyris initiated with Buy into ‘biotech beauty boom’ at Canaccord

Canaccord analyst Susan Anderson initiated coverage of Amyris with a Buy rating and $1.50 price target. Amyris is a consumer biotechnology company that develops and manufactures sustainable ingredients mainly for beauty and food and has also developed consumer brands focused on clean, green, and sustainability, the analyst tells investors in a research note. As consumers continue to gravitate toward clean, green, and sustainable products, a "biotech beauty boom is on the horizon," says the firm. It believes Amyris "can emerge a winner" given its sustainable molecule offering, combined with its clean consumer offering.